Back to List View Graph View

Histone deacetylase

Histone deacetylases (HDACs) are enzymes that regulate protein acetylation and function as important epigenetic regulators of cellular state, including fungal growth and pathogenicity.

Where the papers sit

9 papers from the last 6 months study histone deacetylase directly · updated from PubMed 13 Nov 2026

Study type 0 clinical trials · 9 preclinical

Themes one subject · 1 paradigm shift · 1 new direction

Those 9 are all about one subject.

  • HDAC Therapeutic Discovery

    HDAC-directed research is broadening from nonspecific inhibition toward isoform-selective, fungal-specific, multitarget, and sustained-release agents. HDAC11 inhibitors, Hos3 structures, hydroxamic acid derivatives, and SAHA nanoparticles illustrate efforts to improve selectivity, potency, and exposure. Antitumor studies connect HDAC suppression with G2/M arrest, mitochondrial disruption, NQO1/STAT3 signaling, and sensitization to antibody-drug conjugates. Other work tests HDAC inhibition against doxorubicin cardiotoxicity and neurovascular injury, leaving tissue-specific efficacy and safety as open questions.

    9 papers

PARADIGM SHIFT

HDAC inhibition can protect injured tissues rather than merely suppress pathological cell growth

The doxorubicin-induced cardiotoxicity model treated with suberoylanilide hydroxamic acid and the endothelin-1 ischemic-stroke model treated with apicidin show, independently, that HDAC inhibition can be tissue-protective rather than principally cytotoxic. In the cardiac model, suberoylanilide hydroxamic acid required HDAC4 and restored transcriptional control by disrupting 14-3-3 interactions with HDAC4/5, thereby reducing cardiotoxicity; in the stroke model, apicidin preserved neuronal ultrastructure despite persistent vascular injury. Together, these findings replace the set’s dominant antitumor framing with a context-dependent view in which HDAC inhibition can protect specific nonmalignant tissues through organ-specific mechanisms. 42697879Sep 42219139May

NEW DIRECTION

Fungal-specific Hos3 makes histone deacetylase a pathogen-selective antifungal target

The Aspergillus fumigatus Hos3–T2383 system gives histone deacetylase a role as a structurally distinct, fungus-restricted therapeutic target rather than as a general mammalian cancer or tissue-response target. AfHos3 lacks a clear mammalian ortholog, shows species-specific catalytic and inhibitor sensitivities, and uses a fungal-specific substrate and inhibitor pocket containing an essential F371/F443 aromatic clamp. This shifts HDAC-directed intervention toward pathogen-selective antifungal design, with structural features that may permit targeting the fungus without relying on mammalian HDAC inhibition. 42876389Oct

Papers

The 9 papers from the last 6 months that study histone deacetylase directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

HDAC Therapeutic Discovery (9)
  1. Development of a Potent and Isoform-Selective HDAC11 Inhibitor with Anti-Tumor Efficacy against Non-Small Cell Lung Cancer. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018564
  2. Structural and mechanistic basis of selective inhibition of the fungal-specific histone deacetylase Hos3 from the pathogenic fungus Aspergillus fumigatus. Protein science : a publication of the Protein Society · 15 Oct 2026 PMID 42876389
  3. HDAC inhibition via suberoylanilide hydroxamic acid ameliorates doxorubicin-induced cardiotoxicity. Nature communications · 4 Sept 2026 PMID 42697879
  4. Exploration of novel hydroxamic acid-based candidates integrating chalcone scaffold cap as multitarget HDAC inhibitors: design, anti-prostatic cancer assessment, in silico docking and molecular dynamic simulation. Journal of enzyme inhibition and medicinal chemistry · 28 Aug 2026 PMID 42661166
  5. Spatial proteogenomic profiling uncovers sensitization strategies for antibody-drug conjugate in HER2-positive breast cancer. Cell reports. Medicine · 13 Aug 2026 PMID 42594874
  6. SAHA-coupled biocompatible cellulose-based nanoparticles as HDAC-inhibitory drug delivery systems with slow and sustained release behavior. Carbohydrate polymers · 12 Aug 2026 PMID 42586627
  7. Discovery of novel NQO1/STAT3/HDAC triple-target agents for the treatment of triple negative breast cancer. Bioorganic chemistry · 24 Jun 2026 PMID 42341572
  8. A piperazine-triazole hybrid triggers G2/M arrest in triple-negative breast Cancer cells by suppressing HDAC activity and disrupting mitochondrial membrane potential. Bioorganic chemistry · 19 Jun 2026 PMID 42320117
  9. Divergent neurovascular protection: Histone deacetylase inhibition preserves neuronal ultrastructure while hypoxia-inducible factor activation maintains vascular integrity after ischemic stroke. Brain research · 31 May 2026 PMID 42219139

By study type

Preclinical: animal, cell and lab studies (9)
  1. Development of a Potent and Isoform-Selective HDAC11 Inhibitor with Anti-Tumor Efficacy against Non-Small Cell Lung Cancer. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018564
  2. Structural and mechanistic basis of selective inhibition of the fungal-specific histone deacetylase Hos3 from the pathogenic fungus Aspergillus fumigatus. Protein science : a publication of the Protein Society · 15 Oct 2026 PMID 42876389
  3. HDAC inhibition via suberoylanilide hydroxamic acid ameliorates doxorubicin-induced cardiotoxicity. Nature communications · 4 Sept 2026 PMID 42697879
  4. Exploration of novel hydroxamic acid-based candidates integrating chalcone scaffold cap as multitarget HDAC inhibitors: design, anti-prostatic cancer assessment, in silico docking and molecular dynamic simulation. Journal of enzyme inhibition and medicinal chemistry · 28 Aug 2026 PMID 42661166
  5. Spatial proteogenomic profiling uncovers sensitization strategies for antibody-drug conjugate in HER2-positive breast cancer. Cell reports. Medicine · 13 Aug 2026 PMID 42594874
  6. SAHA-coupled biocompatible cellulose-based nanoparticles as HDAC-inhibitory drug delivery systems with slow and sustained release behavior. Carbohydrate polymers · 12 Aug 2026 PMID 42586627
  7. Discovery of novel NQO1/STAT3/HDAC triple-target agents for the treatment of triple negative breast cancer. Bioorganic chemistry · 24 Jun 2026 PMID 42341572
  8. A piperazine-triazole hybrid triggers G2/M arrest in triple-negative breast Cancer cells by suppressing HDAC activity and disrupting mitochondrial membrane potential. Bioorganic chemistry · 19 Jun 2026 PMID 42320117
  9. Divergent neurovascular protection: Histone deacetylase inhibition preserves neuronal ultrastructure while hypoxia-inducible factor activation maintains vascular integrity after ischemic stroke. Brain research · 31 May 2026 PMID 42219139